Genetic Variations Associated with Resistance to Doxorubicin and Paclitaxel in Breast Cancer
Anthracycline- and taxane-based regimens have been the mainstay in treating breast cancer patients using chemotherapy. Yet, the genetic make-up of patients and their tumors may have a strong impact on tumor sensitivity to these agents and to treatment outcome. This study represents a new paradigm as...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_ca |
| Published: |
2012
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/1807/33810 |